Media About Us


  • 01 September 2016

    FDA-Approved Raindrop Near Vision Inlay Corrects Blurry Reading Vision -- Now Available in Utah for the First Time

    FDA-Approved Raindrop Near Vision Inlay Corrects Blurry Reading Vision -- Now Available in Utah for the First Time

    Yahoo Finance

    Most people begin to notice a decline in their near vision in their early 40s and 50s, which typically occurs as a result of a frustrating but inevitable age-related change in vision called presbyopia. Fortunately, recent advancements in technology provide surgical options to improve near vision and offer patients restored visual independence. On June 29, 2016, The U.S. Food and Drug Administration (FDA) approved the Raindrop® Near Vision Inlay -- a surgical implant produced by ReVision Optics, Inc. -- used to help improve near vision in patients between the ages of 45-65 years old who suffer from presbyopia.

  • 23 August 2016

    Jeffrey Whitman, M.D., Will Be the First Dallas Eye Doctor to Implant Commercial RaindropЃ Near Vision Inlays in U.S.

    Jeffrey Whitman, M.D., Will Be the First Dallas Eye Doctor to Implant Commercial RaindropЃ Near Vision Inlays in U.S.

    PRWEB

    Following extensive clinical trials, the Food and Drug Administration (FDA) approved the Raindrop Near Vision Inlay, a tiny, clear, implantable medical device, to improve near vision in some patients with presbyopia. FDA approval was granted June 29, 2016.

  • 11 August 2016

    Follow the Money: US Companies Shrug Off Politics and Invest in Russia

    Follow the Money: US Companies Shrug Off Politics and Invest in Russia

    Sputnik

    In spite of the US government's best efforts to sanction the Russian economy, many US companies are continuing or even increasing their investment in Russia, wrote Forbes columnist Kenneth Rapoza.

  • 01 August 2016

    Will Liquid Biopsies Transform Oncology Clinical Trials?

    Will Liquid Biopsies Transform Oncology Clinical Trials?

    Ed Miseta / Clinical Leader

    Epic Sciences says it has developed a technology that CEO Murali Prahalad believes will transform oncology trials by identifying and characterizing circulating tumor cells. Those cells have been long recognized as a key part of cancer metastasis. Tumors shed these cells into the circulatory system where they then travel to different parts of the body and, under the right conditions, become the genesis of new tumors.

  • 20 July 2016

    Pfizer Partners with NovaMedica to Build Manufacturing Unit in Russia

    Jerry Boling / Market Digest

    Pfizer Inc. (NYSE: PFE) is currently in the process of developing several manufacturing units in a number of geographical territories all over the world. Just recently, the pharmaceutical giant inked its third major deal in the in the past couple of years. This huge deal involves a partnership with NovaMedica of Russia to establish a manufacturing facility in the country.

  • 19 July 2016

    Pfizer agrees to license 30 products to Russian pharma company

    Pfizer agrees to license 30 products to Russian pharma company

    Life Sciences IP Review

    US drugs company Pfizer has entered into a manufacturing and licensing agreement with Russian pharmaceutical company NovaMedica. Pfizer has proposed to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region.

  • 19 July 2016

    Pfizer, NovaMedica Announce Strategic Partnership in Russia

    Pfizer, NovaMedica Announce Strategic Partnership in Russia

    Drug Discovery & Development

    Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have announced the start of a long-term strategic partnership to locally manufacture and bring to the Russian market a number of important medicines. The first step will be the construction of a modern pharmaceutical manufacturing plant located in the Vorsino industrial park, Kaluga Region. 

  • 18 July 2016

    Pfizer Inc. (PFE) Ready to Reconnoiter Russian Therapeutic Markets

    Pfizer Inc. (PFE) Ready to Reconnoiter Russian Therapeutic Markets

    Raheel Farooq / Business Finance News

    As restrictions in the Western countries rise and growth remains stagnant, Pfizer has taken a wise step to slowly and steadily enter Russia with the establishment of a manufacturing unit. Pfizer Inc. is in the process to develop manufacturing facilities in numerous geographical territories around the globe. Recently, the drug maker signed its third mega deal in the past several years, which is an agreement with Russia’s NovaMedica to build a manufacturing unit.

  • 18 July 2016

    Pfizer strikes second deal this year for drug production in Russia

    Pfizer strikes second deal this year for drug production in Russia

    Eric Palmer / Fierce Pharma

    Pfizer was a little behind some of its peers in establishing local manufacturing in Russia but it's on a roll now, having just announced its third deal in several years. It is hammering out an agreement with Russia’s NovaMedica for a new manufacturing plant. 

  • 15 July 2016

    Atlas Genetics mandates UBS for up to USD 30m raise Ч source

    Atlas Genetics mandates UBS for up to USD 30m raise Ч source

    Mergermarket

    Atlas Genetics (AG), a UK-based, PE-backed point-of-care (POC) diagnostics company, is looking to raise up to USD 30m to fund clinical trials and commercialization, a source familiar with the situation said. The company has developed ultra-rapid, low cost, multiple analyte detection technology for POC use to screen the presence of sexually transmitted infections (STIs) and hospital acquired infections (HAIs).